Causes of death after first time venous thromboembolism

doi:10.21203/rs.3.rs-3052643/v1

Download PDF

Research Article

Causes of death after first time venous thromboembolism

https://doi.org/10.21203/rs.3.rs-3052643/v1

This work is licensed under a CC BY 4.0 License

You are reading this latest preprint version

Background: Causes of death after first time community-acquired venous thromboembolism (VTE) diagnosed in unselected patients at the emergency department (ED) was investigated.

Material and Methods: The study consists of all patients>18 years of age who had a visit for any medical reason to any of 5 different ED in Stockholm County, Sweden from 1^st January 2016 to 31^st December 2017. We have identified all patients with a first registered incident VTE; deep vein thrombosis (DVT) and/or pulmonary embolism (PE) during the study period.

Cox regression models were used to estimate hazards ratios (HR) with 95% confidence intervals (CIs) for all-cause mortality and cause-specific death in patients with DVT or PE using all other patients as the reference group.

Results: In total, 409,971 patients had an ED visit during the study period of whom 2% were diagnosed with VTE (DVT= 4,817, PE= 3,147). During a mean follow up of 2.6 years, 1265 (16%) and 25,191 (6.3%) patients died within the VTE and reference group, respectively. The adjusted risk of all-cause mortality was nearly double in patients with DVT (HR 1.7; 95% CI, 1.5-1.8) and 3-fold in patients with PE (HR 2.8; 95% CI, 2.6-3.0). While the risk of cancer related death was nearly 3-fold in patient with DVT (HR 2.7; 95% CI, 2.4-3.1), and 5-fold in PE (HR 4.6; 95% CI, 4.1-5.1 respectively). A diagnosis of PE at the ED visit was associated with a 50% increased risk of cardiovascular death (HR 1.50; 95% CI, 1.2-1.9).

Conclusion: Patients with VTE have a high risk of all-cause mortality including cardiovascular death. The study findings indicate that cardiovascular preventive measures have to be improved in patients with VTE.

Venous thromboembolism

pulmonary embolism

deep vein thrombosis

cardiovascular death

emergency visit

Acute venous thromboembolism (VTE) is comprised of deep vein thrombosis (DVT) and pulmonary embolism (PE). VTE is considered the third leading cause of vascular disease after myocardial infarction (MI) and stroke (1). VTE is seen in all age categories but more frequent among elderly and the incidence of VTE is expected to be rising with an ageing population (2, 3). Guidelines recommend direct oral anticoagulation (DOAC) over vitamin K antagonist (VKA) in VTE management (4, 5). DOAC treatment require less dose adjustment, monitoring and dietary restriction, DOAC is also associated with a lower risk of major bleeding events (5).

Mortality and causes of death in patients diagnosed with VTE at the ED are largely unknown in the contemporary era of DOAC. Prior recent studies investigating cause-specific death in VTE-patients have generally been small and have mainly reported short-term mortality. A large study of patients diagnosed with first time VTE between 1980–2011 reported a mortality rate ratio within 1 to 10 years of VTE-diagnosis to be 36% higher for DVT and 41% higher for PE compared to the general population (6). Available data suggest that cancer is the leading causes of death in elderly VTE patients (7). Deaths in direct conjunction with VTE events are attributed to PE, although there is a huge uncertainty and presumably a high rate of misdiagnosis of the causes of death associated with PE (8). A prior meta-analysis showed no effect of VTE prevention on mortality, suggesting that VTE can be seen rather as a marker of mortality than the actual cause of death (9).

Clinical course and outcomes vary in VTE-patients depending on underlying diseases and provoking factors (7, 10). Previous reports indicate that patients with VTE and weak risk factors for VTE such as infection have a higher rate of VTE-recurrence compared to patients with VTE and a strong risk factor such as certain surgery (11). In patients with VTE and no identifiable risk factor for VTE indefinite anticoagulation should be considered according to guidelines (4). In Sweden these patients and patients with complicated VTE are usually followed by anticoagulation clinics while most cases of uncomplicated VTE are followed by general practitioners’ centers.

Despite improvement in VTE diagnostics and new treatment options, mortality associated with VTE is still high and remains a major health concern (1, 12). Recent available data principally relies on short-term follow-up in VTE-patients treated with DOAC (13, 14). We aimed to investigate all-cause mortality and causes of death among patients with DVT and PE in a large cohort of patients visiting EDs in Stockholm County.

Study population

All patients > 18 years old visiting any of 5 different EDs in Stockholm, Sweden (at Karolinska University Hospital, Danderyd Hospital, South Hospital, S:t Göran Hospital and Södertälje Hospital) for any medical reason from 1st January 2016 to 31st December 2017 were included. Within this cohort, patients with a first-time DVT or PE diagnosis during the study period were identified. Patients were followed until 31st of December 2018. The study was approved by the local Ethics Committee in Region Stockholm and conformed to the ethical guidelines of the 1975 Declaration of Helsinki.

Data Sources

Patients’ data from the ED visit was collected from the central IT department of Region Stockholm after approval from local hospital´s authorities. The patients’ national identity numbers were compiled and sent to the Swedish National Board of Health and Welfare for linkage to data on patients’ comorbidities from the Swedish National Patient Register (NPR: which comprises all health care data of inpatient and outpatient specialist care), prescribed medications from the Prescribed Drug Register and to causes and dates of death from the Cause-of-Death Register. In the Cause-of-Death Register, all causes of death are classified and coded according to the 10th version of the International Classification of Disease (ICD-10).

Exposure

The exposure was defined as VTE diagnosed in the absence of a priorly registered VTE diagnosis in the NPR during the study period. Patients with VTE were then further categorized into DVT and PE respectively. Patients with concurrent DVT and PE were included in the PE-group. The follow-up for the exposed group started at the first visit with a VTE diagnosis registered and for the unexposed group at the index date (i.e., at the time of the first ED visit during the study period.

Definitions

VTE was defined according to the ICD-codes registered in the NPR during the study period: PE (I26.9 and I26.0) and DVT (I80.2; I80 (I80.0 excluded), I82 (I82.1 excluded). Medications dispensed within 6 months prior to the index date were regarded as medications at baseline except DOAC, low-molecular weight heparin (LMWH) and warfarin where all prescriptions claimed within 60 days from the index date are reported. Apixaban, Dabigatran, Rivaroxaban and Edoxaban were the available DOACs for VTE treatment in Sweden during the study period. Comorbidities (diabetes, hypertension, heart failure, chronic obstructive pulmonary disease, chronic kidney disease, stroke, myocardial infarction, atrial fibrillation, and cancer) were defined according to ICD-codes in the NPR with at least one registration as a main or secondary diagnosis in NPR for up to 3 years prior to the index date (Supp document 1).

Outcomes

The primary and secondary outcomes were all-cause mortality and cause-specific mortality, respectively. Mortality was ascertained by using the Causes of Death Register. Cardiovascular death was defined as death with an underlying cause of death in the I-chapter, or R960-R91, according to ICD-10. Cancer-related death was defined as ICD code (C00-C97) in the Causes of Death Register. Any other death was defined as non-cardiovascular non-cancer related death. (Supp document 1)

Statistical analysis

Descriptive statistics were performed using means and standard deviations for summarizing numerical variables, and frequencies and percentages for categorical variables. Incidence rates were calculated for all-cause mortality and cause-specific deaths. Kaplan-Meier curves were constructed to visualize survival from all causes of death and cardiovascular death in the exposed and unexposed groups. The log rank test was used to test for differences between DVT and PE. Cox proportional hazard models were used to estimate the risk of all cause death, cardiovascular death, and cancer related death in the DVT and PE group in reference to the control group. Adjustments were made for age, sex, comorbidities (diabetes, hypertension, heart failure, chronic obstructive pulmonary disease, chronic kidney disease, stroke, myocardial infarction, atrial fibrillation and cancer) and medications at baseline (anticoagulants, beta-blockers, angiotensin converting enzyme inhibitors and statin) in the constructed models. P-values < 0.05 were considered significant in the analysis. The collected data was analyzed with STATA version 13.1 software (Stata Corporation, College Station, TX).

Study population:

During the study period altogether 409,971 patients visited EDs in Stockholm of whom 7964 (2%) were diagnosed with a first time VTE (Table 1). Patients with VTE were older and more likely to be men compared to the control group. The most common comorbidities among the VTE-patients were hypertension, diabetes, atrial fibrillation, and cancer. DOAC was the most frequent anticoagulation prescribed followed by LMWH and Warfarin. At index date 14,863 (3.7%) of the patients in the control group had a cancer diagnosis whereas 326 patients (6,8%) in the DVT group and 299 patients (9.5%) in the PE group had a cancer diagnosis (Table 1).

Table 1

Baseline characteristics of the patients included in the study.
Variables	All patients	Control	DVT	PE
Number of patients, n (%)	409,971 (100)	402,007 (98.1)	4,817 (1.2)	3,147 (0.8)
Age, years (mean, SD)	51.1 (20.8)	50.9 (20.8)	60.9 (17.3)	65.0 (16.6)
Age 18–49	201,729 (49.2)	199,911 (49.7)	1,263 (26.2)	555 (17.6)
Age 50–79	165,555 (40.4)	160,660 (40.0)	2,882 (59.8)	2,014 (64.0)
Age 80+	42,686 (10.4)	41,436 (10.3)	672 (14.0)	578 (18.4)
Male sex, n (%)	172,671 (42.9)	168,654 (42.8)	2,426 (50.4)	1,591 (50.6)
MI	1,195 (0.3)	1,186 (0.3)	3 (0.1)	6 (0.2)
CIHD	3,013 (0.7)	2,953 (0.7)	24 (0.5)	36 (1.1)
Atrial_fibrillation	7,886 (1.9)	7,768 (1.9)	57 (1.2)	61 (1.9)
COPD	2,666 (0.7)	2,577 (0.6)	32 (0.7)	57 (1.8)
Diabetes	9,333 (2.3)	9,163 (2.3)	86 (1.8)	84 (2.3)
HF	3,842 (1.0)	3,757 (0.9)	32(0.7)	53(1.7)
Hypertension	12,061 (2.9)	11,742 (2.9)	144 (3.0)	175 (5.6)
CVD	3,279 (0.8)	3,205 (0.8)	48 (1.0)	26 (0.8)
Obesity	1,597 (0.4)	1,572 (0.4)	15 (0.3)	10 (0.3)
Renal_disease	2,817 (0.7)	2,736 (0.7)	49 (1.0)	32 (1.0)
Peripheral_Vascular_disease	825 (0.2)	799 (0.2)	18 (0.4)	8 (0.3)
Liver disease	749 (0.2)	728 (0.2)	15 (0.3)	6 (0.2)
Cancer	15,488 (3.8)	14,863 (3.7)	326 (6.8)	299 (9.5)
Stroke	3,729 (0.8)	3,205 (0.8)	48 (1.0)	26 (0.82)
B2_blocker	38,357 (9.4)	37,484 (9.3)	442 (9.2)	431 (13.7)
A2_inhibitor	9,882 (2.4)	9,624 (2.4)	128 (2.7)	130 (4.1)
ACE_inhibitor	18,081 (4.4)	17,574 (4.4)	266 (5.5)	241 (7.7)
Calcium_antagonist	20,193 (4.9)	19,661 (4.9)	287 (6.0)	245 (7.8)
Loop_diuretica	15,625 (3.8)	15,182 (3.8)	229 (4.8)	214 (6.8)
Statin	19,017 (4.6)	18,549 (4.6)	254 (5.3)	214 (6.8)
Aspirin	26,645 (6.5)	26,050 (6.5)	343 (7.1)	252 (8.0)
LMWH	8,318 (2.0)	6,405 (1.6)	1,571 (33)	703 (22)
DOAC	22,206 (5.4)	19,258 (4.8)	2,109 (44)	1,640 (52)
Warfarin	8,322 (2)	11,351 (3)	274 (6)	275 (9.0)
MI = myocardial infarction, CIHD = Chronic ischemic heart disease, COPD = chronic obstructive pulmonary disease, HF = heart failure, CVD = cardiovascular disease, LMWH = low molecular weight heparin, DOAC = direct oral anticoagulation, DVT = deep vein thrombosis, PE = pulmonary embolism

All-cause mortality

During a mean follow-up of 2.6 years, one-fifth (22%) of all PE patients died, while 12% and 6.3% of patients were died in the DVT group and in the control group, respectively (Fig. 2, Table 2a). The all-cause mortality rate was more than doubled in the DVT and PE groups in comparison to the control group (Table 2b). The risk of all-cause mortality was higher for both DVT, and PE patients compared to the control group after adjusting for age and sex, and in the fully adjusted model (Table 3).

Table 2

a: Cumulative deaths, non-cardiovascular, cardiovascular, all cancer and other deaths reported among the 409,971 patients who sought care at a participating emergency department in Stockholm, Sweden from 1st January 2016 to 31th December 2017. In parenthesis is the proportion of deaths in relation to the number of patients in each group: control, DVT, PE and total population respectively.
	Control (n = 402,007)	DVT (n = 4,817)	PE (n = 3,147)	Total (n = 409,971)
All-cause mortality	25,191 (6.3)	574 (11.9)	691 (22.0)	26,456 (6.5)
Non-CV death	19,795 (4.9)	511 (10.6)	621 (20)	20,927 (5.1)
CV death	5,396 (1.3)	63 (1.3)	70 (2.2)	5,529 (1.3)
All cancer death	7,280 (1.8)	312 (6.4)	357 (11.3)	7,949 (1.9)
Other death	17,911 (4.45)	262 (5.4)	334 (10.6)	18,507 (4.5)

Table 2

b. Number (%) of deaths and incidence rates (95% CI) per 100 person-years stratified by outcome (i.e., control, DVT, and PE) and type of death (i.e., all-cause, non-CV death, CV death, all cancer death, and other death) among 409,971 patients who sought care at a participating emergency department in Stockholm, Sweden during 1st January 2016 to 31st December 2017.
Type of death	n (%)	Rate/100 py (95% CI)
Type of death	Total	Control	DVT	PE
All cause death	26,456 (6.5)	2.6 (2.6–2.6)	6.1(5.7–6.7)	12.4(11.5–13.3)
Non-CV death	20,927 (5.1)	2.1(2.0-2.1)	5.5(5.0–6.0)	11.1(10.3–12.0)
CV death	5,529 (1.3)	0.6(0.5–0.6)	0.7(0.5–0.9)	1.3(1.0-1.6)
All cancer death	7,949 (1.9)	0.8(0.7–0.8)	3.3(3.0-3.7)	6.5(5.8–7.2)
Other death	18,507 (4.5)	1.8(1.8–1.9)	2.8( 2.5–3.2)	5.9(5.3–6.6)
CI = confidence interval, CV = cardiovascular, VTE = venous thromboembolism, PE = pulmonary embolism

Table 3

Long term risk of death due to CV and cancer in DVT and PE patients in the study. Multivariable model adjusted by comorbidities (diabetes, hypertension, heart failure, chronic obstructive pulmonary disease, chronic kidney disease, stroke, myocardial infarction, atrial fibrillation, and cancer) and medications at baseline (anticoagulants, beta-blockers, angiotensin converting enzyme inhibitors and statin). CI = confidence interval, CV = cardiovascular, DVT = deep vein thrombosis, PE = pulmonary embolism, HR = hazard ratio.
	Control	DVT	PE
Crude HR (95% CI)	Ref	2.4 (2.2–2.6)	4.8 (4.4–5.2)
Age- and sex-adjusted HR (95% CI)	Ref	1.7 (1.6–1.9)	2.9 (2.7–3.1)
*Multivariable adjusted HR (95% CI)		1.7 (1.5–1.8)	2.8 (2.6-3.0)
CV death
Crude HR (95% CI)	Ref	1.2 (1.0-1.6)	2.3 (1.8–2.9)
Age- and sex-adjusted HR (95% CI)	Ref	0.9 (0.7–1.2)	1.4 (1.1–1.8)
*Multivariable adjusted HR (95% CI)		1.0 (0.8–1.3)	1.5 (1.2–1.9)
All cancer death
Crude HR (95% CI)	Ref	4.5 (4.0–5.0)	8.6 (7.7–9.6)
Age- and sex-adjusted HR (95% CI)	Ref	3.2 (2.9–3.6)	5.4 (4.9-6.0)
*Multivariable adjusted HR (95% CI)		2.7 (2.4–3.1)	4.6 (4.1–5.1)

Cancer-related death and cardiovascular death

In the control group, 7280 (1.8%) patients died of cancer-related causes within the study period compared to 312 (6.5%) and 357 (11.3%) patients in the DVT and PE group, respectively (Fig. 3, Table 2a). The fully adjusted risk of cancer-related death was almost 3-fold higher in the DVT group and almost 5-fold higher in the PE group compared to the control group (HR 2.7, 95% CI: 2.4–3.1; and HR 4.6, 95% CI: 4.1–5.1) respectively (Table 3). The rate of non-cancer related death was higher in both the DVT, and PE group compared to the control group (Table 2b).

A total of 5396 (1.3%) patients died of cardiovascular cause in the control group, compared to 63 (1.3%) patients in the DVT group and 70 (2.2%) patients in the PE group (Fig. 4, Table 2a). The cardiovascular mortality rate was higher in the PE group compared to the control group; however, no difference was observed between the DVT group and the reference (Table 2b). The fully adjusted risk of cardiovascular death was 50% increased (HR: 1.5, 95% CI: 1.2–1.9) in patients with PE compared to the control group (Table 3). In patients with DVT the fully adjusted risk of cardiovascular death was not increased in comparison to the control group (HR: 1.0, 95% CI: 0,8 − 1,3).

In a large cohort of patients in Stockholm County of inhabitant 2.2 million we found that a final diagnosis of PE was associated with an almost 3-fold increased risk of all-cause mortality, and a 50% increased risk of cardiovascular death compared to patients without VTE. Patients with DVT had an increased adjusted risk of all-cause mortality, but no increased risk of cardiovascular death. Cancer-related mortality was increased both in DVT and PE patients.

Most prior studies on mortality and causes of death in patients with VTE are conducted before the introduction of DOAC as a treatment of VTE. In two small cohort studies the 1-year all-cause mortality was 22% and 24% in patients with a first time VTE (15, 16). A large prospective cohort study published in 2013 showed a 3-month all-cause mortality of 8% in patients with VTE (17). A metanalysis including 10 trials and 35,029 patients had similar case fatality rate (16%) among patients with VTE that were treated with DOACs as we report in our study (18). In Sweden most of the community-acquired DVT-cases are diagnosed as outpatient facilities (often situated or connected to a hospital ED) and few at general practitioner’s centers, while PE is most often diagnosed at EDs and in hospitalized patients. Considering that our study population is solely comprised of patients presenting to the ED, the severity of disease in patients diagnosed with VTE may differ from that in other study settings.

The observation of a higher risk of cancer-related death in the DVT and PE-group compared to the control group was expected. Our results are consistent with the results from a prior large cohort study in which cancer was the most frequent cause of death in VTE patients within 30 days and at 1 year (10). In our study the number of cancer-related deaths exceeded that of patients with known cancer disease at baseline within the VTE-group which suggests that a considerable proportion of patients were diagnosed with cancer after the VTE-diagnosis. An earlier study showed that the survival of patients diagnosed with cancer at the time of the VTE-diagnosis is poorer than that of matched control patients with the same type and stage of cancer (19).

We found that the adjusted risk of cardiovascular death was 50% increased in patients with PE compared to patients in the control group, whether this is attributed to acute death from PE or from cardiovascular events such as acute heart failure, MI, or stroke, is unknown. The number of PE-related deaths are generally few, and approximately contribute to less than 0.4% of all deaths in Sweden (20). Due to a steady decline in autopsy rates in Sweden (21) the cause of death in many of the patients with PE is not certain. A prior study found an in-hospital mortality rate of only 1,1% in patients presenting with PE in the ED (22), which might suggest that acute death from PE could not fully explain the increased risk of cardiovascular death among patients with PE observed in our study. A previous small scale study reported that 40% of mortality is related to cardiovascular disease after PE, with a mean follow-up time of 3.8 years (23). An increased risk of arterial cardiovascular events in patients with unprovoked VTE was previously reported in a meta-analysis (24). If this can be assigned to similar risk factors for VTE and atherothrombotic disease, or if VTE could act as a trigger for atherothrombotic disease is unknown. Another meta-analysis showed a positive association between the presence of major risk factors of atherothrombotic disease, especially hypertriglyceridemia, and the risk of a VTE event (25). In our study the increased risk for cardiovascular death remained after adjustments for common risk factors of atherosclerosis, MI, and stroke such as hypertension, diabetes, and previous MI.

Age-standardized PE-related mortality has been decreasing in Europe since 2000 (26) and according to the Swedish healthcare annual statistic report a trend in reduced DVT-related mortality has been observed in the last few years (20). We did not have data before the introduction of DOAC, which limited our ability to investigate a potential change in VTE related mortality associated with current treatment strategies.

We do acknowledge that the observed increased all-cause mortality risk in VTE-patients was reflected in all categories of cause-specific death. A more detailed categorization of CV death would have been more informative; however, the absolute numbers of outcomes were relatively small which limited the ability to explore more details on cause-specific deaths. Nonetheless, in contrast to the expected excessive risk of cancer-related death found in the exposed group, we believe that the paralleled increased adjusted risk of CV death is a novel finding that would merit further attention. We believe that the later finding emphasizes that improvements in tailored preventative strategies for cardiovascular risk modification and monitoring are needed in these patients.

Strengths and limitations of the study

This is an observational cohort study, cautious interpretations of data in the context of any clinical setting should be considered, mainly because of the inherent risk with residual confounding that we could not control for. The study was conducted in a large cohort of patients with a relative long follow-up time which allowed us to calculate risk estimates the events with high precision. A strength of our study is that the source of our data, the Swedish registers, are known to be of high quality, including the Swedish Prescribed Drug Register (27, 28). The Cause-of-Death Register has excellent nationwide coverage with virtually no loss to follow-up (21). There are however reports of some degree of misclassification of VTE diagnoses in the Swedish NPR, specifically for DVT but also to some extent for PE (29).

We did not have data available from primary healthcare, as this is not included in the Swedish NPR. Consequently, misclassification of the exposure may have occurred, i.e. as some patients may have had a DVT diagnosed solely within primary care during the study period or even before our study started. Although we were able to control for the most important confounders in our statistical models, we do not have information regarding stage or type of cancer. It was not possible to conclude with certainty that the severity of cancers was similar between the DVT and PE group, mortality differences could be related to a worse prognosis of the cancer itself rather than the VTE. We acknowledge that both the differences in age, burden of cardiovascular comorbidities and prevalent cancer at baseline would all be contributing factors to the observed differences in outcomes between the groups. Competing risk events in the analysis of causes of death was not addressed in our analysis, however, we have adjusted for all these variables in our statistical models. In our belief the fully adjusted models sufficiently handle the confounding effect of these factors and provide adequate estimates on the association between exposure and the outcomes of interest. We consider that the findings in our study on Swedish data are generalizable to other countries with similar health care system.

In this large cohort study with unselected patients in the ED we found an increased adjusted risk of death among patients with VTE. Besides an expected association between a VTE diagnosis and cancer-related death we observed that patients with PE had a fifty percent elevated adjusted risk of cardiovascular death compared to non-VTE patients. Our findings indicate that improved cardiovascular preventative measures in patients who suffer from VTE events are needed.

Funding: No specific funding was obtained for this study. Dr Roos holds research positions funded by the Stockholm County Council (grant: 20200935). Dr. Gigante hold grant from Stiftelsen Sigurd och Elsa Goljes Minne, Stiftelsen prof Nanna Svartz fond. The sponsor had no role in the design or conduct of this study.

Disclosures: Nothing to declare.

Author Contributions

Study concept and design: Siddiqui. Acquisition of data: Siddiqui, Heurlin, Okas. Analysis and interpretation of data: all authors. Drafting of the manuscript: Siddiqui, Lonnberg and Roos. Critical revision of the manuscript for important intellectual content: all authors.

Acknowledgments: Our sincere gratitude to Dr. Gaetano Marrone, PhD, at the Department of Public Health Sciences, Karolinska Institute, Stockholm, Sweden for data management and analysis support.

Di Nisio M, van Es N, Büller HR (2016) Deep vein thrombosis and pulmonary embolism. Lancet 388(10063):3060–3073
Deitelzweig SB, Johnson BH, Lin J (2011) Prevalence of clinical venous thromboembolism in the USA:Current trends and future projections. Am J Hematol 86(2):217–219
Huang W, Goldberg RJ, Anderson FA, Kiefe CI, Spencer FA (2014) Secular trends in occurrence of acute venous thromboembolism: The worcester VTE study (1985–2009). Am J Med 127(9):829–839e5
Konstantinides SV, Meyer G, Bueno H, Galié N, Gibbs JSR, Ageno W et al (2020) 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS). Eur Heart J 41(4):543–603
Ortel TL, Neumann I, Ageno W, Beyth R, Clark NP, Cuker A et al (2020) American society of hematology 2020 guidelines for management of venous thromboembolism: Treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 4(19):4693–4738
Søgaard KK, Schmidt M, Pedersen L, Horváth-Puhó E, Sørensen HT (2014) 30-Year mortality after venous thromboembolism a population-based cohort study. Circulation 130(10):829–836
Faller N, Limacher A, Méan M, Righini M, Aschwanden M, Beer JH et al (2017) Predictors and Causes of Long-Term Mortality in Elderly Patients with Acute Venous Thromboembolism: A Prospective Cohort Study. Am J Med [Internet]. ;130(2):198–206. Available from: http://dx.doi.org/10.1016/j.amjmed.2016.09.008
Kraaijpoel N, Tritschler T, Guillo E, Girard P, Le Gal G (2019) Definitions, adjudication, and reporting of pulmonary embolism–related death in clinical studies: A systematic review. J Thromb Haemost 17(10):1590–1607
Klemen ND, Feingold PL, Hashimoto B, Wang M, Kleyman S, Brackett A et al (2020) Mortality risk associated with venous thromboembolism: a systematic review and Bayesian meta-analysis. Lancet Haematol [Internet]. ;7(8):e583–93. Available from: http://dx.doi.org/10.1016/S2352-3026(20)30211-8
Tagalakis V, Patenaude V, Kahn SR, Suissa S (2013) Incidence of and mortality from venous thromboembolism in a real-world population: The Q-VTE study cohort. Am J Med [Internet]. ;126(9):832.e13-832.e21. Available from: http://dx.doi.org/10.1016/j.amjmed.2013.02.024
Kearon C, Ageno W, Cannegieter SC, Cosmi B, Geersing GJ, Kyrle PA (2010) Risk of Recurrence After a First Episode of Symptomatic Venous Thromboembolism Provoked by a Transient Risk Factor. Arch Intern Med 170(19):1710–1716
Raskob GE, Angchaisuksiri P, Blanco AN, Buller H, Gallus A, Hunt BJ, Hylek EM, Kakkar A, Konstantinides SV, McCumber M, Ozaki Y, Wendelboe A, Weitz JI, ISTH Steering Committee for World Thrombosis Day (2014) Nov;34(11):2363-71 ;. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol. doi: 10.1161/ATVBAHA.114.304488. PMID: 25304324
Roetker NS, Lutsey PL, Zakai NA, Alonso A, Adam (2018) TJ MRA-CMR with DOA and W in the PT of VTTH ;118(9):1637–1645. All-cause mortality risk with direct oral anticoagulants and warfarin in the primary treatment of venous thromboembolism. 2019;118(9):1637–45
Bounameaux H, Haas S, Farjat AE, Ageno W, Weitz JI, Goldhaber SZ et al (2020) Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE. Thromb Res [Internet]. ;191(March):103–12. Available from: https://doi.org/10.1016/j.thromres.2020.04.036
Næss IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J (2007) Incidence and mortality of venous thrombosis: A population-based study. J Thromb Haemost 5(4):692–699
Arshad N, Bjøri E, Hindberg K, Isaksen T, Hansen JB, Brækkan SK (2017) Recurrence and mortality after first venous thromboembolism in a large population-based cohort. J Thromb Haemost 15(2):295–303
Gussoni G, Frasson S, La Regina M, Di Micco P, Monreal M (2013) Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. Thromb Res [Internet]. ;131(1):24–30. Available from: http://dx.doi.org/10.1016/j.thromres.2012.10.007
Gómez-Outes A, Lecumberri R, Suárez-Gea ML, Terleira-Fernández AI, Monreal M, Vargas-Castrillón E (2015) Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism. J Cardiovasc Pharmacol Ther 20(5):490–500
Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA (2000) Dec;343(25):1846–1850 Prognosis of cancers associated with venous thromboembolism. The New England Journal of Medicine. DOI: 10.1056/nejm200012213432504. PMID: 11117976
Socialstyrelsen (2022) Statistical Database, Cause of Death [Internet]. 220622. Available from: https://sdb.socialstyrelsen.se/if_dor/val_eng.aspx
Brooke HL, Talbäck M, Hörnblad J, Johansson LA, Ludvigsson JF, Druid H et al (2017) The Swedish cause of death register. Eur J Epidemiol 32(9):765–773
Pollack CV, Schreiber D, Goldhaber SZ, Slattery D, Fanikos J, O’Neil BJ et al (2011) Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: Initial report of EMPEROR (multicenter emergency medicine pulmonary embolism in the real world registry). J Am Coll Cardiol [Internet]. ;57(6):700–6. Available from: http://dx.doi.org/10.1016/j.jacc.2010.05.071
Chwan Ng AC, Chung T, Yong ASC, Wong HSP, Celermajer DS, Kritharides L (2011) Long-term cardiovascular and noncardiovascular mortality of 1023 patients with confirmed acute pulmonary embolism. Circ Cardiovasc Qual Outcomes 4(1):122–128
Becattini C, Vedovati MC, Ageno W, Dentali F, Agnelli G (2010) Incidence of arterial cardiovascular events after venous thromboembolism: A systematic review and a meta-analysis. J Thromb Haemost 8(5):891–897
Mi Y, Yan S, Lu Y, Liang Y, Li C (2016) Venous thromboembolism has the same risk factors as atherosclerosis. Med (Baltim) 95(32):e4495
Barco S, Mahmoudpour SH, Valerio L, Klok FA, Münzel T, Middeldorp S et al (2020) Trends in mortality related to pulmonary embolism in the European Region, 2000–15: analysis of vital registration data from the WHO Mortality Database. Lancet Respir Med 8(3):277–287
Wallerstedt SM, Wettermark B, Hoffmann M (2016) The First Decade with the Swedish Prescribed Drug Register – A Systematic Review of the Output in the Scientific Literature. Basic Clin Pharmacol Toxicol 119(5):464–469
Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, Persson I, Sundström A, Westerholm B, Rosén M (2007) Jul;16(7):726 – 35 The new Swedish Prescribed Drug Register–opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. doi: 10.1002/pds.1294. Erratum in: Pharmacoepidemiol Drug Saf. 2008 May;17(5):533. MichaelFored, C [corrected to Fored, Carl Michael]. PMID: 16897791. research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2006
Öhman L, Johansson M, Jansson JH, Lind M, Johansson L (2018) Positive predictive value and misclassification of diagnosis of pulmonary embolism and deep vein thrombosis in swedish patient registries. Clin Epidemiol 10:1215–1221

Supplementdocument1.docx

Download PDF

Reviewers agreed at journal
30 Jun, 2023
Reviewers invited by journal
28 Jun, 2023
Editor assigned by journal
14 Jun, 2023
First submitted to journal
13 Jun, 2023

You are reading this latest preprint version

Causes of death after first time venous thromboembolism

Status:

Version 1

Abstract

Figures

INTRODUCTION

MATERIALS AND METHODS

Study population

Data Sources

Exposure

Definitions

Outcomes

Statistical analysis

RESULTS

Study population:

All-cause mortality

Cancer-related death and cardiovascular death

DISCUSSION

Strengths and limitations of the study

CONCLUSION

Declarations

References

Supplementary Files

Status:

Version 1